The Innovative FEED Act of 2025 adds a new statutory category—"zootechnical animal food substance" (ZAFS)—to the Federal Food, Drug, and Cosmetic Act and treats those products as food additives governed by section 409. The bill sets a substantive definition focused on products added to animal feed or water that act solely in the gastrointestinal tract to alter digestive byproducts, reduce foodborne pathogens, or change the gut microbiome without providing nutritive value; it also lists categorical exclusions (for example, drugs, hormones, ionophores) and allows the Secretary to add exclusions by rulemaking.
Practically, the bill requires petitioners to submit efficacy-oriented data (including quantity required and full reports of investigations with methods and controls), authorizes FDA to specify conditions of use that ensure the substance achieves its intended effect, mandates a standardized labeling statement disavowing disease treatment claims, and makes absence of that statement a misbranding violation. The package creates a new regulatory path for microbiome-targeted feed products but shifts evidentiary burdens onto manufacturers and administrative burdens onto FDA while tightening the legal boundary between feed additives and animal drugs.
At a Glance
What It Does
The bill defines "zootechnical animal food substance" and deems it a food additive under section 409, requiring a formal petition that must include data on the intended effect and quantity needed and full reports of investigations. It adds a mandatory labeling statement forbidding disease-treatment claims and authorizes FDA to specify conditions of use and to exclude categories by notice-and-comment rulemaking.
Who It Affects
Feed manufacturers and agritech startups developing microbiome-targeted additives, livestock producers who would use such products, animal health companies and veterinarians navigating claim boundaries, and FDA (which will handle new petitions and rulemakings). Exporters and importers may also be affected by the clarified regulatory status for trade and compliance.
Why It Matters
The bill carves out a statutory pathway distinct from the animal-drug approval process, potentially accelerating commercialization of gut-targeted feed products while forcing manufacturers to produce efficacy data and altering enforcement priorities. It reshapes the regulatory boundary between feeds and drugs, with downstream impacts on product claims, testing, and international market access.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new definition—"zootechnical animal food substance"—into section 201 of the Federal Food, Drug, and Cosmetic Act. That definition targets substances added to animal feed or drinking water that act only in the gastrointestinal tract to change digestive byproducts, reduce human-health-relevant foodborne pathogens in food animals, or alter the gut microbiome’s structure or function without serving as a nutritive ingredient.
The definition is deliberately functional: it focuses on intended effect, site of action (gut only), and the absence of nutritive purpose.
The statute explicitly excludes a set of product types from the new category: substances intended to diagnose, cure, mitigate, treat, or prevent animal disease; hormones; ionophores; and active moieties that are or were the subject of certain animal-drug approvals or investigations. The Secretary of Health and Human Services can add more exclusions through notice-and-comment rulemaking, which leaves room for future boundary-setting between animal drugs and these feed-directed microbiome products.Amendments to section 409 treat a ZAFS as a food additive and modify petition requirements and FDA’s review authority.
Petitions must include all relevant data on the intended effect and the quantity required to produce it, plus full reports of investigations with methods and controls — language that pushes beyond the safety-oriented submissions typical for many food additives toward efficacy documentation. FDA’s rulemaking authority is adjusted so that, when issuing a regulation, the agency must set the conditions under which the substance may be used to achieve its intended effect; and the agency may deny a petition if the petitioner fails to establish that the proposed use will achieve that effect.The bill also prescribes one-liner labeling: each ZAFS must state, verbatim, that it is "Not for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals," and FDA may allow statements describing the intended effects on animal structure or function.
Missing the required statement renders the product misbranded under the amended section 403. Finally, a separate clause clarifies that the Secretary may not compel the use of any such additive, preserving producer choice while creating a new approval pathway.
The Five Things You Need to Know
The bill defines a zootechnical animal food substance by three cumulative tests: added to feed or drinking water, intended to change digestive byproducts/reduce foodborne pathogens/alter the gut microbiome (not for nutritive value), and acting solely inside the gastrointestinal tract.
It excludes substances intended to treat disease, hormones, ionophores, and active moieties tied to approved or publicly investigated animal drugs, and lets the Secretary add more exclusions through notice-and-comment rulemaking.
A ZAFS is "deemed to be a food additive" under section 409; petitions must provide 'all relevant data' on the effect and the quantity required and include full reports of investigations with methods and controls.
FDA may deny a petition if the petitioner 'fails to establish' that the proposed use, under the regulation’s conditions of use, will achieve the intended effect; regulations must specify how to use the substance to produce that effect.
Labeling must include the exact statement: 'Not for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals.' Omission of that statement makes the product misbranded.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act's short titles: the "Innovative Feed Enhancement and Economic Development Act of 2025" and the "Innovative FEED Act of 2025." This is purely captioning; it has no regulatory effect but signals the bill’s stated policy focus on feed innovation and economic development.
Creates 'zootechnical animal food substance' definition
Adds a detailed functional definition to the FD&C Act that sets three substantive criteria (route of administration, intended effects, and site of action) and explicitly limits the category to substances that work solely within the gastrointestinal tract. The definition anchors all downstream obligations: once a product fits this definition it follows the new pathway; whether a product fits will often be a factual and scientific determination with real regulatory consequences.
New petition standards and labeling rules for ZAFS
Modifies petition content and review in section 409 to require efficacy-oriented submissions for ZAFS, including data on effect size, required doses, and full investigational reports with methods and controls. The agency's authority to issue a regulation is adjusted so regulations must set explicit conditions of use and, uniquely for ZAFS, can be denied if the petitioner cannot show the product will achieve its stated effect. The section also adds a labeling subsection that mandates a specific disease-disclaimer while permitting claims about structure/function effects as defined in the new 201(tt).
Missing required labeling becomes misbranding
Adds a new ground for misbranding: if a product is a ZAFS and it lacks the statutory disclaimer on its labeling, it is misbranded. That creates an enforcement hook for FDA inspectors and private litigants and makes compliance with the single-sentence label a legal requirement, not merely guidance.
Secretary may not require use of ZAFS
Clarifies that nothing in the amendments gives HHS authority to compel the use of any zootechnical food substance. This provision preserves producer and market choice and limits possible administrative mandates, which has practical implications for procurement, extension programs, and any future public-health-driven pressure to adopt feed additives.
This bill is one of many.
Codify tracks hundreds of bills on Agriculture across all five countries.
Explore Agriculture in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Feed additive developers and agritech startups — The statutory category creates a clearer, dedicated regulatory pathway that can reduce uncertainty about whether a microbiome-targeted product will be treated as a drug, potentially lowering entry barriers and accelerating commercialization for companies focused on gut-targeted innovations.
- Livestock producers and integrators — If ZAFS products meet their intended effects (for example, reduced foodborne pathogens or favorable digestive byproducts), producers could see on-farm food-safety benefits and production efficiencies without undergoing the longer animal-drug approval process; they also retain the choice to use or not use such additives.
- Exporters and supply-chain participants — A defined U.S. regulatory status can facilitate documentation for cross-border shipments and buyer contracts by clarifying whether a product is a feed additive rather than a veterinarian-prescribed drug, reducing some regulatory ambiguity in trade relations.
Who Bears the Cost
- Feed manufacturers and marketers — Companies must generate robust efficacy data (quantity/dose, full investigation reports with methods and controls) to obtain regulations, which raises R&D and compliance costs compared with simple supplement claims, and adds labeling compliance obligations with legal risk for omission.
- FDA and USDA (regulatory agencies) — FDA will shoulder increased review, rulemaking, and enforcement work to evaluate efficacy claims, draw lines with animal-drug law, and develop guidance; USDA and state animal-health authorities may face coordination demands and possible resource reallocation.
- Veterinary pharmaceutical companies and veterinarians — The statutory exclusions and new category could compress certain product markets, trigger disputes over claim boundaries, and require veterinarians to advise clients on the legal status and appropriate uses of ZAFS versus drugs, raising liability and practice-management questions.
Key Issues
The Core Tension
The central dilemma is between incentivizing rapid commercialization of gut-targeted, animal-feed innovations (which could reduce foodborne pathogens and foster ag-tech growth) and preserving rigorous, science-based protections around efficacy, safety, and the long-standing legal distinction between drugs and food additives. The bill lowers one kind of barrier while pushing regulators into difficult scientific and legal boundary-drawing with no easy compromise between speed and protective certainty.
The bill shifts a substantial part of the approval calculus onto efficacy demonstration for products that have historically been regulated largely for safety as food additives. That raises scientific and administrative complications: microbiome endpoints are complex, variable across species and farms, and often lack standardized, validated assays.
FDA will be asked to evaluate not only toxicology and residue safety but also whether a product reliably produces a specific microbiome change or pathogen reduction under real-world conditions. Designing petition standards that are rigorous yet feasible for industry will require detailed guidance and probably additional rulemaking.
The statutory effort to draw a bright line between drugs and these feed-directed microbiome products creates implementation risk. The exclusions (disease-treatment intent, hormones, ionophores, active moieties tied to animal drugs) are clear in text but will produce hard fact patterns where claims, dosing, or effects straddle categories.
Enforcement will depend on interpreting "intended effect" and whether an effect constitutes treatment rather than structure/function modulation. Internationally, the new U.S. category could collide with trading partners' feed and drug regimes and with residue or maximum-residue-limit systems, creating potential trade and testing disputes.
Finally, although the bill prohibits forced adoption, minimal labeling combined with permissive structure/function claims may still generate marketing claims that confuse purchasers and blur the practical difference from animal drugs, increasing litigation and enforcement demand.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.